Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
And is there any role in utilizing FGFR2 inhibitors in first line setting?
The PROOF trial utilizing Infigratinib in first line was stopped after the company discontinued the development of the drug.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on · Updated on
I have not been able to find an answer to this question. The NCCN and French National Clinical Practice Guidelines both continue to recommend first line treatment with Gemcitabine/Cisplatin and Durvalumab. Exceptions include NTRK gene fusions and MSI-H/dMMR where NTRK inhibitors (e.g. entrectinib, l...
Join for free or sign in to see the full answer